Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 3;12(4):789.
doi: 10.3390/biomedicines12040789.

Correlation between rCBV Delineation Similarity and Overall Survival in a Prospective Cohort of High-Grade Gliomas Patients: The Hidden Value of Multimodal MRI?

Amina Latreche  1 , Gurvan Dissaux  1 , Solène Querellou  2   3 , Doria Mazouz Fatmi  4 , François Lucia  1   5 , Anais Bordron  1 , Alicia Vu  1 , Ruben Touati  1 , Victor Nguyen  1 , Mohamed Hamya  1 , Brieg Dissaux  3   4 , Vincent Bourbonne  1   5
Affiliations

Correlation between rCBV Delineation Similarity and Overall Survival in a Prospective Cohort of High-Grade Gliomas Patients: The Hidden Value of Multimodal MRI?

Amina Latreche et al. Biomedicines. .

Abstract

Purpose: The accuracy of target delineation in radiation treatment planning of high-grade gliomas (HGGs) is crucial to achieve high tumor control, while minimizing treatment-related toxicity. Magnetic resonance imaging (MRI) represents the standard imaging modality for delineation of gliomas with inherent limitations in accurately determining the microscopic extent of tumors. The purpose of this study was to assess the survival impact of multi-observer delineation variability of multiparametric MRI (mpMRI) and [18F]-FET PET/CT.

Materials and methods: Thirty prospectively included patients with histologically confirmed HGGs underwent a PET/CT and mpMRI including diffusion-weighted imaging (DWI: b0, b1000, ADC), contrast-enhanced T1-weighted imaging (T1-Gado), T2-weighted fluid-attenuated inversion recovery (T2Flair), and perfusion-weighted imaging with computation of relative cerebral blood volume (rCBV) and K2 maps. Nine radiation oncologists delineated the PET/CT and MRI sequences. Spatial similarity (Dice similarity coefficient: DSC) was calculated between the readers for each sequence. Impact of the DSC on progression-free survival (PFS) and overall survival (OS) was assessed using Kaplan-Meier curves and the log-rank test.

Results: The highest DSC mean values were reached for morphological sequences, ranging from 0.71 +/- 0.18 to 0.84 +/- 0.09 for T2Flair and T1Gado, respectively, while metabolic volumes defined by PET/CT achieved a mean DSC of 0.75 +/- 0.11. rCBV variability (mean DSC0.32 +/- 0.20) significantly impacted PFS (p = 0.02) and OS (p = 0.002).

Conclusions: Our data suggest that the T1-Gado and T2Flair sequences were the most reproducible sequences, followed by PET/CT. Reproducibility for functional sequences was low, but rCBV inter-reader similarity significantly impacted PFS and OS.

Keywords: MRI; PET-FET; [18F]-FET PET/CT; delineation; glioblastoma; high-grade gliomas; magnetic resonance imaging; rCBV; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest regarding the present study.

Figures

Figure 1
Figure 1
Volume target variability between readers for each sequence. (A). T1-weighted imaging (T1Gado). (B). T2-weighted fluid-attenuated inversion recovery (T2Flair). (C). Relative cerebral blood volume (rCBV) corrected for contrast leakage shows. (D). Permeability estimation map (k2). (E). Diffusion-weighted imaging (DWI b1000). (F). Apparent diffusion coefficient (ADC) map. (G). 18F-FET PET/CT.
Figure 2
Figure 2
Progression-free survival curve regarding rCBV’s DSC using Kaplan–Meier. Abbreviation: rCBV: relative cerebral blood volume.
Figure 3
Figure 3
Overall survival curve regarding rCBV’s DSC using Kaplan–Meier. Abbreviation: rCBV: relative cerebral blood volume.
See this image and copyright information in PMC

References

    1. Schritz A., Aouali N., Fischer A., Dessenne C., Adams R., Berchem G., Huiart L., Schmitz S. Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma. Neuro-Oncol. Adv. 2021;3:vdab052. doi: 10.1093/noajnl/vdab052. - DOI - PMC - PubMed
    1. Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial—PubMed. [(accessed on 31 July 2021)]; Available online: https://pubmed.ncbi.nlm.nih.gov/19269895/ - PubMed
    1. Tu Z., Xiong H., Qiu Y., Li G., Wang L., Peng S. Limited recurrence distance of glioblastoma under modern radiotherapy era. BMC Cancer. 2021;21:720. doi: 10.1186/s12885-021-08467-3. - DOI - PMC - PubMed
    1. Minniti G., Amelio D., Amichetti M., Salvati M., Muni R., Bozzao A., Lanzetta G., Scarpino S., Arcella A., Enrici R.M. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother. Oncol. 2010;97:377–381. doi: 10.1016/j.radonc.2010.08.020. - DOI - PubMed
    1. Pauleit D., Floeth F., Hamacher K., Riemenschneider M.J., Reifenberger G., Müller H.-W., Zilles K., Coenen H.H., Langen K.-J. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–687. doi: 10.1093/brain/awh399. - DOI - PubMed

LinkOut - more resources